About the Authors
- John Gatfield
-
* E-mail: john.gatfield@actelion.com
Affiliation Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
- Celia Mueller Grandjean
-
Affiliation Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
- Thomas Sasse
-
Affiliation Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
- Martine Clozel
-
Affiliation Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
- Oliver Nayler
-
Affiliation Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
Competing Interests
All authors are employees of Actelion Pharmaceuticals Ltd. Bosentan is a marketed product of Actelion Pharmaceuticals Ltd., macitentan is a product in development by Actelion Pharmaceuticals, and both compounds are under protection by patents licensed in or held by Actelion Pharmaceuticals Ltd. (bosentan: patent family corresponding to EP 526708 (F. Hoffmann-La Roche AG); macitentan: patent family corresponding to WO 02/053557 (Actelion Pharmaceuticals Ltd)). This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: JG. Performed the experiments: CMG TS. Analyzed the data: CMG TS JG. Wrote the paper: JG ON MC.